Actively Recruiting
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Led by University of Florida · Updated on 2025-10-15
550
Participants Needed
3
Research Sites
312 weeks
Total Duration
On this page
Sponsors
U
University of Florida
Lead Sponsor
O
Oregon Health and Science University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Muscular Dystrophy (MD). The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with DMD with muscles of healthy individuals of the same age and monitor disease progression in those with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements. Additionally, the investigators will map the progression of Becker MD following adults with this rare disease. The primary objective is to conduct a multi-centered study to validate the potential of non-invasive magnetic resonance imaging and magnetic resonance spectroscopy to monitor disease progression and to serve as a noninvasive surrogate outcome measure for clinical trials in DMD and BMD. The secondary objective is to characterize the progressive involvement of the lower extremity, upper extremity, trunk/respiratory muscles in boys/men with DMD and BMD guiding clinical trials.
CONDITIONS
Official Title
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males aged 5 to 30 years diagnosed with Duchenne muscular dystrophy based on clinical features, elevated serum creatine kinase, or genetic confirmation
- Ambulatory or non-ambulatory males with Duchenne muscular dystrophy
- Ambulatory males aged 18 to 62 years with Becker muscular dystrophy without lower extremity disease or injury
- Specific recruitment of Becker muscular dystrophy patients with deletion mutations in dystrophin gene exon 45 or 51
- Ambulatory healthy males aged 18 to 62 years without lower or upper extremity disease or injury as controls
You will not qualify if you...
- Males with contraindications to MRI
- Males with unstable medical conditions
- Males unable to cooperate during testing
- Males with secondary conditions affecting muscle metabolism, function, or ability (e.g., cerebral palsy, endocrine disorders, mitochondrial disease)
- Males requiring daytime ventilation
- Males with implantable cardioverter defibrillators or pacemakers
- Healthy males who participate in competitive sports training exceeding 8 hours per week
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Florida
Gainesville, Florida, United States, 32610
Actively Recruiting
2
Oregon Health and Science University
Portland, Oregon, United States, 97239
Actively Recruiting
3
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Active, Not Recruiting
Research Team
K
Krista Vandenborne, PhD
CONTACT
K
Kelly Rock, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here